Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx onl...

FDA Drug Recall #D-0116-2025 - Class II, September 11, 2024

Recall Summary

Recall Number D-0116-2025
Classification Class II - Moderate risk
Date Initiated September 11, 2024
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Mckesson Medical-Surgical Inc. Corporate Office
Location Richmond, VA
Product Type Drugs
Quantity 5 cartons/20 units each carton

Product Description

Hylenex recombinant (hyaluronidase) injection, 150 USP units/mL, 4x1 mL Single Dose Vials, Rx only, Manufactured for and marketed by Halozyme, Inc., 12390 El Camino Real San Diego California 92130, Distributed by Antares Pharma, Inc., Ewing, NJ NDC 18657-117-04

Reason for Recall

cGMP Deviations: Temperature excursion

Distribution Pattern

Virgina

Lot / Code Information

Serial # 100000831961 100000820688 100000820689 100000820515

Other Recalls from Mckesson Medical-Surgical Inc. Corpor...

Recall # Classification Product Date
D-0400-2025 Class II Medroxyprogesterone Acetate Injectable Suspensi... Apr 25, 2025
D-0401-2025 Class II Infuvite Adult, multiple vitamins injection, Ba... Apr 25, 2025
D-0538-2025 Class II PROLIA (denosumab), injection, 60mg/mL, For Sub... Apr 21, 2025
D-0539-2025 Class II EVENITY, (romosozumab -aqqg) injection, 105mg/1... Apr 21, 2025
D-0540-2025 Class II BENLYSTA (belimumab) for injection, 400 mg/20 ... Apr 21, 2025

Frequently Asked Questions

cGMP stands for Current Good Manufacturing Practice, the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful, in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.